NRD
ESPR

Nebula Research & Development’s Esperion Therapeutics ESPR Stock Holding History

Nebula Research & Development’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-13,974
Closed -$37.5K – 861
2024
Q1 		$37.5K Buy
+13,974
New +$34K 0.01% 703

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nebula Research & Development's ESPR Position: Q2 2024 in Review

Nebula Research & Development sold out of Esperion Therapeutics (ESPR) in Q2 2024, closing a stake of 13,974 shares — an estimated $37.5K sold.

Nebula Research & Development first reported a position in ESPR in Q1 2024 and held it in 1 quarter. The position peaked at $37.5K in Q1 2024. 176 funds tracked by Wall St. Rank hold ESPR as of Q2 2024.

  • Nebula Research & Development reported no remaining Esperion Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Nebula Research & Development sold 13,974 Esperion Therapeutics shares in Q2 2024, an estimated $37.5K.
  • Nebula Research & Development first reported a position in Esperion Therapeutics in Q1 2024 and held it in 1 quarter.
  • Nebula Research & Development's Esperion Therapeutics position peaked at $37.5K in Q1 2024.
  • 176 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2024.

Based on Nebula Research & Development's 13F filing for Q2 2024, filed 14 Aug 2024.